Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

HIV-Associated Vacuolar Encephalomyelopathy.

Madden GR, Fleece ME, Gupta A, Lopes MBS, Heysell SK, Arnold CJ, Wispelwey B.

Open Forum Infect Dis. 2019 Aug 16. pii: ofz366. doi: 10.1093/ofid/ofz366. [Epub ahead of print]

PMID:
31419292
2.

Quality Assessment of Dried Blood Spots from Tuberculosis Patients from Four Countries.

Zuur MA, Veenhof H, Aleksa A, Boveneind-Vrubleuskaya NV', Darmawan E, Hasnain MG, Heysell SK, Jongedijk EM, Koster RA, Magis-Escurra C, Martinez N, Molinas G, Mondal D, Mulyani UA, Perwitasari DA, Tsivunchyk A, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Jun 4. doi: 10.1097/FTD.0000000000000659. [Epub ahead of print]

PMID:
31169760
3.

Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.

Al-Shaer MH, Alghamdi WA, Alsultan A, An G, Ahmed S, Alkabab Y, Banu S, Barbakadze K, Houpt E, Kipiani M, Mikiashvili L, Cegielski JP, Kempker RR, Heysell SK, Peloquin CA.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00279-19. doi: 10.1128/AAC.00279-19. Print 2019 Jul.

4.
5.

Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.

Alghamdi WA, Alsultan A, Al-Shaer MH, An G, Ahmed S, Alkabab Y, Banu S, Barbakadze K, Houpt E, Kipiani M, Mikiashvili L, Schmidt S, Heysell SK, Kempker RR, Cegielski JP, Peloquin CA.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00055-19. doi: 10.1128/AAC.00055-19. Print 2019 May.

6.

Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.

Juma SP, Maro A, Pholwat S, Mpagama SG, Gratz J, Liyoyo A, Houpt ER, Kibiki GS, Mmbaga BT, Heysell SK.

BMC Infect Dis. 2019 Feb 7;19(1):129. doi: 10.1186/s12879-019-3757-1.

7.

Meta-narrative review of molecular methods for diagnosis and monitoring of multidrug-resistant tuberculosis treatment in adults.

Mbelele PM, Mohamed SY, Sauli E, Mpolya EA, Mfinanga SG, Addo KK, Heysell SK, Mpagama SG.

Int J Mycobacteriol. 2018 Oct-Dec;7(4):299-309. doi: 10.4103/ijmy.ijmy_135_18.

8.

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302. doi: 10.1093/cid/ciy611.

PMID:
30496461
9.

d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Deshpande D, Alffenaar JC, Köser CU, Dheda K, Chapagain ML, Simbar N, Schön T, Sturkenboom MGG, McIlleron H, Lee PS, Koeuth T, Mpagama SG, Banu S, Foongladda S, Ogarkov O, Pholwat S, Houpt ER, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316. doi: 10.1093/cid/ciy624.

PMID:
30496460
10.

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Srivastava S, Bendet P, Koeuth T, Lee PS, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S317-S326. doi: 10.1093/cid/ciy609.

PMID:
30496457
11.

Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.

Justine M, Yeconia A, Nicodemu I, Augustino D, Gratz J, Mduma E, Heysell SK, Kivuyo S, Mfinanga S, Peloquin CA, Zagurski T, Kibiki GS, Mmbaga B, Houpt ER, Thomas TA.

J Pediatric Infect Dis Soc. 2018 Nov 5. doi: 10.1093/jpids/piy106. [Epub ahead of print]

PMID:
30395239
12.

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec.

13.

New epidemic cluster of pre-extensively drug resistant isolates of Mycobacterium tuberculosis Ural family emerging in Eastern Europe.

Sinkov V, Ogarkov O, Mokrousov I, Bukin Y, Zhdanova S, Heysell SK.

BMC Genomics. 2018 Oct 22;19(1):762. doi: 10.1186/s12864-018-5162-3.

14.

Therapeutic Drug Monitoring: The Need for Practical Guidance.

Alffenaar JC, Heysell SK, Mpagama SG.

Clin Infect Dis. 2019 Mar 5;68(6):1065-1066. doi: 10.1093/cid/ciy787. No abstract available.

PMID:
30219826
15.
16.

Pharmacokinetics of tuberculosis drugs in HIV-infected patients from Irkutsk, Russian Federation: redefining drug activity.

Lyles G, Ogarkov O, Zhdanova S, Peloquin CA, Ebers A, Pfaeffle H, Al-Shaer MH, Moiseeva E, Zorkaltseva E, Koscheev M, Houpt ER, Heysell SK.

Eur Respir J. 2018 May 24;51(5). pii: 1800109. doi: 10.1183/13993003.00109-2018. Print 2018 May. No abstract available.

17.

Performance of computed tomography versus chest radiography in patients with pulmonary tuberculosis with and without diabetes at a tertiary hospital in Riyadh, Saudi Arabia.

Alkabab YM, Enani MA, Indarkiri NY, Heysell SK.

Infect Drug Resist. 2018 Jan 3;11:37-43. doi: 10.2147/IDR.S151844. eCollection 2018.

18.

Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh.

Heysell SK, Ahmed S, Rahman MT, Akhanda MW, Gleason AT, Ebers A, Houpt ER, Banu S.

Eur Respir J. 2018 Mar 22;51(3). pii: 1701778. doi: 10.1183/13993003.01778-2017. Print 2018 Mar. No abstract available.

19.

Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment.

Zentner I, Modongo C, Zetola NM, Pasipanodya JG, Srivastava S, Heysell SK, Mpagama S, Schlect HP, Gumbo T, Bisson GP, Vinnard C.

Int J Infect Dis. 2018 Mar;68:18-23. doi: 10.1016/j.ijid.2017.12.017. Epub 2017 Dec 15.

20.

Subacute loss of vision in one eye · rash on hands and feet · plaques with scaling on genitals · Dx?

Nunn A, Sturek JM, Reuss JE, Rein MF, Heysell SK.

J Fam Pract. 2017 Dec;66(12):E9-E11.

PMID:
29202152
21.

Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring.

van den Elsen SHJ, Oostenbrink LM, Heysell SK, Hira D, Touw DJ, Akkerman OW, Bolhuis MS, Alffenaar JC.

Ther Drug Monit. 2018 Feb;40(1):17-37. doi: 10.1097/FTD.0000000000000462. Review.

22.

Efficacy of raltegravir, etravirine and darunavir/ritonavir for treatment-experienced HIV patients from a non-urban clinic population in the United States.

Ebers AM, Alkabab Y, Wispelwey B, Dillingham R, Wang XQ, Schexnayder J, Heysell SK.

Ther Adv Infect Dis. 2017 Sep;4(5):135-142. doi: 10.1177/2049936117718101. Epub 2017 Jul 13.

23.

Correction: Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis.

Operario DJ, Koeppel AF, Turner SD, Bao Y, Pholwat S, Banu S, Foongladda S, Mpagama S, Gratz J, Ogarkov O, Zhadova S, Heysell SK, Houpt ER.

PLoS One. 2017 Jul 7;12(7):e0181284. doi: 10.1371/journal.pone.0181284. eCollection 2017.

24.

Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis.

Operario DJ, Koeppel AF, Turner SD, Bao Y, Pholwat S, Banu S, Foongladda S, Mpagama S, Gratz J, Ogarkov O, Zhadova S, Heysell SK, Houpt ER.

PLoS One. 2017 May 18;12(5):e0176522. doi: 10.1371/journal.pone.0176522. eCollection 2017. Erratum in: PLoS One. 2017 Jul 7;12 (7):e0181284.

25.

Administrative interventions associated with increased initiation on antiretroviral therapy in Irkutsk, Siberia.

Ogarkov OB, Ebers A, Zhdanova S, Moiseeva E, Koshcheyev ME, Zorkaltseva E, Shugaeva S, Vitko S, Lyles G, Houpt ER, Heysell SK.

Public Health Action. 2016 Dec 21;6(4):252-254. doi: 10.5588/pha.16.0050.

26.

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

Alffenaar JC, Tiberi S, Verbeeck RK, Heysell SK, Grobusch MP.

Clin Infect Dis. 2017 Jan 1;64(1):104-105. Epub 2016 Oct 6. No abstract available.

27.

Glycated hemoglobin screening identifies patients admitted for retreatment of tuberculosis at risk for diabetes in Tanzania.

Sariko ML, Mpagama SG, Gratz J, Kisonga R, Saidi Q, Kibiki GS, Heysell SK.

J Infect Dev Ctries. 2016 Apr 28;10(4):423-6. doi: 10.3855/jidc.7324.

28.

Listeria monocytogenes Endovascular Graft Infection.

Heysell SK, Hughes MA.

Open Forum Infect Dis. 2015 Dec 17;3(1):ofv203. doi: 10.1093/ofid/ofv203. eCollection 2016 Jan.

29.

Undertreated HIV and drug-resistant tuberculosis at a referral hospital in Irkutsk, Siberia.

Heysell SK, Ogarkov OB, Zhdanova S, Zorkaltseva E, Shugaeva S, Gratz J, Vitko S, Savilov ED, Koshcheyev ME, Houpt ER.

Int J Tuberc Lung Dis. 2016 Feb;20(2):187-92. doi: 10.5588/ijtld.14.0961.

30.

Diabetes-related tuberculosis in the Middle East: an urgent need for regional research.

Alkabab YM, Al-Abdely HM, Heysell SK.

Int J Infect Dis. 2015 Nov;40:64-70. doi: 10.1016/j.ijid.2015.09.010. Epub 2015 Sep 25. Review.

31.

Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs.

Heysell SK, Pholwat S, Mpagama SG, Pazia SJ, Kumburu H, Ndusilo N, Gratz J, Houpt ER, Kibiki GS.

Antimicrob Agents Chemother. 2015 Nov;59(11):7104-8. doi: 10.1128/AAC.01117-15. Epub 2015 Aug 24.

32.

The Influence of Mining and Human Immunodeficiency Virus Infection Among Patients Admitted for Retreatment of Tuberculosis in Northern Tanzania.

Mpagama SG, Lekule IA, Mbuya AW, Kisonga RM, Heysell SK.

Am J Trop Med Hyg. 2015 Aug;93(2):212-5. doi: 10.4269/ajtmh.15-0189. Epub 2015 May 26.

33.

Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014.

Heysell SK, Moore JL, Peloquin CA, Ashkin D, Houpt ER.

Tuberc Respir Dis (Seoul). 2015 Apr;78(2):78-84. doi: 10.4046/trd.2015.78.2.78. Epub 2015 Apr 2.

34.

Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.

Ndusilo ND, Heysell SK, Mpagama SG, Gratz J, Segesela FH, Pazia SJ, Wang XQ, Houpt ER, Kibiki GS.

PLoS One. 2015 Mar 27;10(3):e0122769. doi: 10.1371/journal.pone.0122769. eCollection 2015.

35.

Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.

Heysell SK, Ahmed S, Ferdous SS, Khan MS, Rahman SM, Gratz J, Rahman MT, Mahmud AM, Houpt ER, Banu S.

PLoS One. 2015 Feb 24;10(2):e0116795. doi: 10.1371/journal.pone.0116795. eCollection 2015.

36.

Having walked the path.

Heysell SK.

Ann Intern Med. 2014 Sep 2;161(5):374-5. doi: 10.7326/M14-0326. No abstract available.

PMID:
25178571
37.

Outbreak of pyrazinamide-monoresistant tuberculosis identified using genotype cluster and social media analysis.

Thomas TA, Heysell SK, Houpt ER, Moore JL, Keller SJ.

Int J Tuberc Lung Dis. 2014 May;18(5):552-8. doi: 10.5588/ijtld.13.0663.

38.

Understanding pharmacokinetics to improve tuberculosis treatment outcome.

Reynolds J, Heysell SK.

Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):813-23. doi: 10.1517/17425255.2014.895813. Epub 2014 Mar 6. Review.

39.

Intensified specimen collection to improve tuberculosis diagnosis in children from Rural South Africa, an observational study.

Thomas TA, Heysell SK, Moodley P, Montreuil R, Ha X, Friedland G, Bamber SA, Moll AP, Gandhi N, Brant WE, Sturm W, Shah S.

BMC Infect Dis. 2014 Jan 9;14:11. doi: 10.1186/1471-2334-14-11.

40.

Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA.

Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER.

Tuberc Res Treat. 2013;2013:129723. doi: 10.1155/2013/129723. Epub 2013 Nov 17.

41.

Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.

Mpagama SG, Ndusilo N, Stroup S, Kumburu H, Peloquin CA, Gratz J, Houpt ER, Kibiki GS, Heysell SK.

Antimicrob Agents Chemother. 2014;58(2):782-8. doi: 10.1128/AAC.01549-13. Epub 2013 Nov 18.

42.

Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory.

Banu S, Rahman SM, Khan MS, Ferdous SS, Ahmed S, Gratz J, Stroup S, Pholwat S, Heysell SK, Houpt ER.

J Clin Microbiol. 2014 Jan;52(1):156-63. doi: 10.1128/JCM.02378-13. Epub 2013 Oct 30.

43.

Primary multidrug-resistant Mycobacterium tuberculosis in 2 regions, Eastern Siberia, Russian Federation.

Zhdanova S, Heysell SK, Ogarkov O, Boyarinova G, Alexeeva G, Pholwat S, Zorkaltseva E, Houpt ER, Savilov E.

Emerg Infect Dis. 2013 Oct;19(10):1649-52. doi: 10.3201/eid1910.121108.

44.

Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania.

Mpagama SG, Houpt ER, Stroup S, Kumburu H, Gratz J, Kibiki GS, Heysell SK.

BMC Infect Dis. 2013 Sep 14;13:432. doi: 10.1186/1471-2334-13-432.

45.

Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania.

Mpagama SG, Heysell SK, Ndusilo ND, Kumburu HH, Lekule IA, Kisonga RM, Gratz J, Boeree MJ, Houpt ER, Kibiki GS.

PLoS One. 2013 May 13;8(5):e62034. doi: 10.1371/journal.pone.0062034. Print 2013.

46.

18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series.

Heysell SK, Thomas TA, Sifri CD, Rehm PK, Houpt ER.

BMC Pulm Med. 2013 Mar 21;13:14. doi: 10.1186/1471-2466-13-14.

47.

Perianal plaques of cytomegalovirus in a patient with central nervous system lymphoma.

Heysell SK, Wispelwey B.

Case Rep Infect Dis. 2012;2012:948530. doi: 10.1155/2012/948530. Epub 2012 May 17.

48.

The future of molecular diagnostics for drug-resistant tuberculosis.

Heysell SK, Houpt ER.

Expert Rev Mol Diagn. 2012 May;12(4):395-405. doi: 10.1586/erm.12.25. Review.

PMID:
22616704
49.

Comparison of overnight pooled and standard sputum collection method for patients with suspected pulmonary tuberculosis in northern Tanzania.

Mpagama SG, Mtabho C, Mwaigwisya S, Mleoh LJ, Boer IM, Heysell SK, Houpt ER, Kibiki GS.

Tuberc Res Treat. 2012;2012:128057. doi: 10.1155/2012/128057. Epub 2012 Jan 19.

50.

Plasma drug activity assay for treatment optimization in tuberculosis patients.

Heysell SK, Mtabho C, Mpagama S, Mwaigwisya S, Pholwat S, Ndusilo N, Gratz J, Aarnoutse RE, Kibiki GS, Houpt ER.

Antimicrob Agents Chemother. 2011 Dec;55(12):5819-25. doi: 10.1128/AAC.05561-11. Epub 2011 Oct 3.

Supplemental Content

Loading ...
Support Center